Wong ND, Fan W, Philip S, et al. - In view of a decrease of cardiovascular disease (CVD) events by 25% in relation to icosapent ethyl (IPE) in persons with prior CVD or diabetes mellitus (DM) in REDUCE-IT trial (reduction of cardiovascular events with icosapent ethyl–intervention), researchers projected the initial and total CVD events that can be prevented in relation to application of REDUCE-IT trial eligibility criteria to US adults. Using NHANES Surveys 1999-2016, US adults with available REDUCE-IT inclusion criteria were identified. Key REDUCE-IT eligibility criteria were met by 319 of 11,445 adults aged ≥ 45 years. Prior CVD was present in 63% and DM + ≥1 risk factor was present in 37% (primary prevention cohort). Experts estimated averting 349,817 (71,391/year) primary CVD outcomes (CVD death, nonfatal myocardial infarction, stroke, revascularization, or unstable angina), including 146,011 (29,798/year) initial events, if these individuals are administered IPE for the REDUCE-IT median trial period of 4.9 years. Overall, it was concluded that IPE can prevent many CVD events in US adults with known CVD or DM and well-controlled LDL-C on statin therapy.